Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation

被引:29
作者
Nelson, Winnie W. [1 ]
Wang, Li [2 ]
Baser, Onur [3 ,4 ]
Damaraju, Chandrasekharrao V. [5 ]
Schein, Jeffrey R. [1 ]
机构
[1] Janssen Sci Affairs LLC, Hlth Econ & Outcomes Res HECOR, Raritan, NJ 08869 USA
[2] STATinMED Res, Plano, TX USA
[3] STATinMED Res, Ann Arbor, MI USA
[4] MEF Univ, Istanbul, Turkey
[5] Janssen Res & Dev LLC, Raritan, NJ USA
关键词
Atrial fibrillation; Clinical outcomes; International normalized ratio; USA; US veterans; Warfarin; RISK-FACTOR; ANTICOAGULATION CONTROL; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULANT; PREDICTING STROKE; INTENSITY; HOSPITALS; QUALITY;
D O I
10.1007/s11096-014-0038-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although efficacious in stroke prevention in non-valvular atrial fibrillation, many warfarin patients are sub-optimally managed. Objective To evaluate the association of international normalized ratio control and clinical outcomes among new warfarin patients with non-valvular atrial fibrillation. Setting Adult non-valvular atrial fibrillation patients (a parts per thousand yen18 years) initiating warfarin treatment were selected from the US Veterans Health Administration dataset between 10/2007 and 9/2012. Method Valid international normalized ratio values were examined from the warfarin initiation date through the earlier of the first clinical outcome, end of warfarin exposure or death. Each patient contributed multiple in-range and out-of-range time periods. Main outcome measure The relative risk ratios of clinical outcomes associated with international normalized ratio control were estimated. Results 34,346 patients were included for analysis. During the warfarin exposure period, the incidence of events per 100 person-years was highest when patients had international normalized ratio < 2:13.66 for acute coronary syndrome; 10.30 for ischemic stroke; 2.93 for transient ischemic attack; 1.81 for systemic embolism; and 4.55 for major bleeding. Poisson regression confirmed that during periods with international normalized ratio < 2, patients were at increased risk of developing acute coronary syndrome (relative risk ratio: 7.9; 95 % confidence interval 6.9-9.1), ischemic stroke (relative risk ratio: 7.6; 95 % confidence interval 6.5-8.9), transient ischemic attack (relative risk ratio: 8.2; 95 % confidence interval 6.1-11.2), systemic embolism (relative risk ratio: 6.3; 95 % confidence interval 4.4-8.9) and major bleeding (relative risk ratio: 2.6; 95 % confidence interval 2.2-3.0). During time periods with international normalized ratio > 3, patients had significantly increased risk of major bleeding (relative risk ratio: 1.5; 95 % confidence interval 1.2-2.0). Conclusion In a Veterans Health Administration non-valvular atrial fibrillation population, exposure to out-of-range international normalized ratio values was associated with significantly increased risk of adverse clinical outcomes.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [41] A High HASBLED Score Identifies Poor Warfarin Control in Patients Treated for Non-Valvular Atrial Fibrillation in Australia and Singapore
    Bernaitis, Nijole
    Ching, Chi Keong
    Chen, Liping
    Hon, Jin Shing
    Teo, Siew Chong
    Badrick, Tony
    Davey, Andrew K.
    Anoopkumar-Dukie, Shailendra
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 (06) : 499 - 504
  • [42] Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents
    Kepez, Alper
    Erdogan, Okan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2013, 13 (04) : 379 - 384
  • [43] Pharmacoeconomic evaluation of dabigatran vs warfarin in cardiovascular events prevention in patients with non-valvular atrial fibrillation
    Belousov, Yu. B.
    Mareev, V. Yu.
    Yavelov, I. S.
    Belousov, D. Yu.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2012, 8 (01) : 37 - 44
  • [44] Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation
    Lu, Y.
    Branstad, R.
    Karim, R. M.
    Asinger, R. W.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (06) : 628 - 636
  • [45] Hospital Length of Stay: Does Rivaroxaban Reduce Inpatient Stay Compared to Warfarin Among Patients With Non-Valvular Atrial Fibrillation?
    Laliberte, Francois
    Pilon, Dominic
    Raut, Monika K.
    Nelson, Winnie W.
    Duh, Mei Sheng
    Schein, Jeff R.
    Lefebvre, Patrick
    CIRCULATION, 2013, 128 (22)
  • [46] Comparison of healthcare costs among patients with non-valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant
    Franchino-Elder, Jessica
    Gilligan, Adrienne
    Song, Xue
    Hartaigh, Briain O.
    Henriques, Caroline
    Sainski-Nguyen, Amy
    Wang, Cheng
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2020, 11 (02) : 133 - 140
  • [47] Should all patients with non-valvular atrial fibrillation be anticoagulated?
    Ederhy, Stephane
    Dufaitre, Ghislaine
    Boyer-Chatenet, Louise
    Meuleman, Catherine
    Di Angelantonio, Emanuele
    Lang, Sylvie
    Boccara, Franck
    Cohen, Ariel
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 143 (01) : 8 - 15
  • [48] Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberte, Francois
    Pilon, Dominic
    Raut, Monika K.
    Nelson, Winnie W.
    Olson, William H.
    Germain, Guillaume
    Schein, Jeff R.
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) : 645 - 653
  • [49] Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
    Samaras, Athanasios
    Vrana, Eleni
    Kartas, Anastasios
    Moysidis, Dimitrios, V
    Papazoglou, Andreas S.
    Doundoulakis, Ioannis
    Fotos, George
    Rampidis, Georgios
    Tsalikakis, Dimitrios G.
    Efthimiadis, Georgios
    Karvounis, Haralambos
    Tzikas, Apostolos
    Giannakoulas, George
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [50] Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation
    Yamashita, Takeshi
    Koretsune, Yukihiro
    Yasaka, Masahiro
    Inoue, Hiroshi
    Kawai, Yohko
    Yamaguchi, Takenori
    Uchiyama, Shinichiro
    Matsumoto, Masayasu
    Ogawa, Satoshi
    CIRCULATION JOURNAL, 2012, 76 (08) : 1840 - 1847